Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prostatype Genomics ABOSTO:PROGEN +1.03% EV-to-OCF is -0.48 as of Aug. 15, 2026. The stock has 5 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Prostatype Genomics AB ranks better than 56.34% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Prostatype Genomics AB's Enterprise Value is kr11.48 Mil.
Prostatype Genomics AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was kr-23.80 Mil. Therefore, Prostatype Genomics AB's EV-to-OCF for today is -0.48.
The historical rank and industry rank for Prostatype Genomics AB's EV-to-OCF or its related term are showing as below:
OSTO:PROGEN'
s EV-to-OCF Range Over the Past 10 Years
Min: -133.19 Med: -5.4 Max: 0.35
Current: -0.48
During the past 7 years, the highest EV-to-OCF of Prostatype Genomics AB was 0.35. The lowest was -133.19. And the median was -5.40.
OSTO:PROGEN's EV-to-OCF is ranked better than 56.34% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.2
vs OSTO:PROGEN: -0.48
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prostatype Genomics AB (OSTO:PROGEN) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prostatype Genomics AB's PE Ratio (TTM) for today is calculated as:
Prostatype Genomics AB's share price for today is kr0.098.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-0.399.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:PROGEN vs TMO, DHR, IDXX: EV-to-OCF Comparison
For the Diagnostics & Research subindustry, Prostatype Genomics AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's EV-to-OCF falls into.
Prostatype Genomics AB's current Enterprise Value is kr11.48 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was kr-23.80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB (OSTO:PROGEN) has a EV-to-OCF of -0.48 as of Aug. 15, 2026. According to the industry distribution chart, Prostatype Genomics AB ranks #93 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 43.7%.
Is Prostatype Genomics AB's EV-to-OCF too high?
Prostatype Genomics AB's current EV-to-OCF is -0.48. Based on the distribution chart, Prostatype Genomics AB ranks #93 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Prostatype Genomics AB's EV-to-OCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #93 out of 213 companies for EV-to-OCF. This puts Prostatype Genomics AB in the upper half of its industry. The industry median EV-to-OCF is 6.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.20, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostatype Genomics AB's current EV-to-OCF is -0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.04, compared to a current price of kr0.10 — trading 145% above its estimated fair value. The current EV-to-OCF is -0.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current EV-to-OCF is -0.48 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
